Last year, research revealed that weight-loss jabs – or GLP-1RAs – such as Wegovy and Ozempic could reduce the risk of heart attack and stroke.
GLP-1RAs are a class of drugs used to treat type 2 diabetes and obesity. An example of an GLP-1RA is semaglutide, found in Wegovy and Ozempic, and tirzepatide, found in Mounjaro.
This group was compared to a control group who used drugs that reduce blood sugar levels.
The researchers also suggest new potential beneficial effects of the jabs, including associations with a lower risk of substance use disorders, psychotic disorders, seizures, bacterial infections and pneumonia.
The findings have been published in Nature Medicine.
GLP-1RAs have gained substantial popularity in the past several years due to their benefit as a weight-loss treatment.
Ozempic, another GLP-1RA, has been approved for diabetics.
They also said future studies should include more-diverse cohorts, as data from the US Department of Veterans Affairs are predominantly from older, white men.
How intermuscular fat increases heart attack risk - and if you could be affected
Read More“That said, the study provides useful reassurance about the safety of this class of drugs,” he added.
“There is also a reassuring reduction in the incidence of several cancers, including pancreatic.
Professor O’Rahilly said future studies of people treated with these drugs for obesity, without accompanying diabetes, are “awaited with interest”.
‘I might have avoided diabetes if I wasn’t stuck on weight-loss waiting list’
By Alannah Francis
A woman who waited for four years on an NHS waiting list for weight-loss support has said she believes she could have avoided developing type 2 diabetes if she was given help sooner.
Hannah Baker, 44, said she has struggled with her weight her whole life.
The mum of two, who enrolled on private medical provider Oviva’s Tier 3 weight management programme in August, has lost 33 pounds and seen her BMI fall since becoming a participant.
Oviva’s weight-loss programme, which is commissioned and accredited by the NHS, is free for patients and can prescribe eligible participants NHS weight-loss injections.
Wegovy patient Hannah Baker, 44, said she has struggled with her weight her whole lifeMs Baker said she felt forgotten while on the NHS waiting list and as though help was “never” going to come – but is now losing weight at a “steady and manageable pace”.
As part of the weight-loss service, she has “a whole team behind you that work with you to reach your goal weight”, including a psychologist and dieticians that provide feedback on her individual meal choices.
She told The i Paper: “I do believe that if I’d had help a little bit sooner then maybe I wouldn’t have got the type 2 diabetes.
“I do think that was definitely diet-related. So, had my diet changed earlier, then maybe it wouldn’t have got to that point.
“I’m lucky that it’s reversible and it’s definitely going that way.”
To read the full story, click here.
Read More Details
Finally We wish PressBee provided you with enough information of ( Weight-loss drugs reduce risk of seizures, drug abuse and heart attacks, study finds )
Also on site :